Abstract
Intrathecal arabinosyl cytosine was administered on a twice weekly schedule, in a dosage range of 5 to 70 mg per square meter of body surface area, to 13 children with meningeal leukemia. Eleven children with acute lymphocytic leukemia had been previously treated with intrathecal methotrexate, and 7 had received cranial or craniospinal radiotherapy. Seven of these 11 children responded with relief of symptoms and reduction of cerebrospinal fluid (CSF) cell count to less than 10 mononuclear cells per mm3 of CSF and less than 2 leukemic cells on one smear of CSF sediment. The median duration of response was 28 days. Vomiting occurred in 5 children after treatment, headache in 2, and fever in one. Neither leukopenia nor other systemic toxicity was observed. It is concluded that intrathecal arabinosyl cytosine has therapeutic activity against meningeal leukemia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
